Andrzej Jakubowski
Jagiellonian University Medical College
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andrzej Jakubowski.
Circulation | 2002
Seth Hallström; Harald Gasser; Christoph Neumayer; Alexander Fügl; J. Nanobashvili; Andrzej Jakubowski; Ihor Huk; Günther Schlag; Tadeusz Malinski
Background—Peroxynitrite generated from nitric oxide (NO) and superoxide (O2−) contributes to ischemia/reperfusion (I/R) injury. Feedback inhibition of endothelial NO synthase by NO may inhibit O2− production generated also by endothelial NO synthase at diminished local l-arginine concentrations accompanying I/R. Methods and Results—During hindlimb I/R (2.5 hours/2 hours), in vivo NO was monitored continuously (porphyrinic sensor), and high-energy phosphates, reduced and oxidized glutathione (chromatography), and I/R injury were measured intermittently. Rabbits receiving human serum albumin (HSA) (controls) were compared with those receiving S-nitroso human serum albumin (S-NO-HSA) beginning 30 minutes before reperfusion for 1 hour or 30 minutes before ischemia for 3.5 hours (0.1 &mgr;mol · kg−1 · h− 1). The onset of ischemia led to a rapid increase of NO from its basal level (50±12 nmol/L) to 120±20 and 220±15 nmol/L in the control and S-NO-HSA–treated groups, respectively. In control animals, NO dropped below basal levels at the end of ischemia and to undetectable levels (<1 nmol/L) during reperfusion. In S-NO-HSA–treated animals, maximal NO levels never decreased below basal concentration and on reperfusion were 100±15 nmol/L (S-NO-HSA preischemia group, 175±15 nmol/L). NO supplementation by S-NO-HSA led to partial and in the preischemia group to total preservation of high-energy phosphates and glutathione status in reperfused muscle (eg, preischemia groups: ATP, 30.23±5.02 &mgr;mol/g versus control, 15.75±4.33 &mgr;mol/g, P <0.0005; % oxidized glutathione, 4.49± 1.87% versus control, 22.84±6.39%, P <0.0001). S-NO-HSA treatment in all groups led to protection from vasoconstriction and reduced edema formation after reperfusion (eg, preischemia groups: interfiber area, 12.94±1.36% versus control, 27.83±1.95%, P < 0.00001). Conclusions—Long-lasting release of NO by S-NO-HSA provides significant protection of skeletal muscle from I/R injury.
Pharmacological Reports | 2010
Magdalena Sternak; Tamara I. Khomich; Andrzej Jakubowski; Malgorzata Szafarz; Wojciech Szczepański; Magdalena Białas; Marta Stojak; Joanna Szymura-Oleksiak; Stefan Chlopicki
Nicotinamide N-methyltransferase (NNMT), which converts nicotinamide (NA) to 1-methylnicotinamide (MNA), is up-regulated in the cirrhotic liver. Because MNA displays PGI(2)-dependent anti-inflammatory effects, the up-regulation of NNMT may play a regulatory role in liver inflammation. In the present work, we analyzed changes in NNMT activity in the liver and concomitant changes in the concentration of endogenous MNA in plasma in T-cell dependent hepatitis induced by concanavalin A (ConA) in BALB/c mice. Furthermore, we tested whether exogenous MNA possessed a protective effect against ConA-induced hepatitis. Development of liver injury induced by ConA (10 mg/kg, iv) was characterized by measurements of plasma concentration of alanine aminotransaminase (ALT), inflammatory cytokines (INF gamma and TNFalpha) and by histopathological examination. ConA-induced hepatitis was characterized by an early activation of inflammatory cytokines (IFN gamma; from below 0.05 ng/ml to 23.72 +/- 8.80 ng/ml; TNFalpha;from 0.07 +/- 0.01 ng/ml to 0.71 +/- 0.12 ng/ml, 2 h after ConA), an elevation of ALT (from 40.65 +/- 3.2 U/l to 5,092.20 +/- 1,129.05 U/l, 8 h after ConA) and by morphological signs of severe liver inflammation and injury (24 h after ConA). In mice injected with ConA, NNMT activity in the liver was up-regulated approximately 2-fold to 3-fold, 8-24 h after ConA injection. The concentration of MNA and its metabolites (Met-2PY and Met-4PY) in plasma were elevated approximately 2-fold 8 h after ConA injection. Exogenous MNA (100 mg/kg, iv) diminished ConA-induced liver injury, and this effect was reversed by an antagonist of the prostacyclin receptor, RO 3244794 (10 mg/kg, po). In conclusion, the present study demonstrated that hepatic NNMT activity and MNA concentration in plasma significantly increased during the progression of ConA-induced hepatitis in mice. This response may play a hepatoprotective role compatible with the PGI(2)-releasing properties of MNA.
Journal of Inorganic Biochemistry | 1998
Janusz Oszajca; Grażyna Stochel; Ewa Wasielewska; Zofia Stasicka; Gryglewski Rj; Andrzej Jakubowski; Katarzyna Cieślik
The [M(CN)xNOy]n- complexes (where M = Cr(I), Mn(I), Mn(II), Fe(I), Fe(II), Fe(III)) were studied as potential NO-donors using both pharmacological and theoretical semi-empirical methods. Only iron complexes appeared to be pharmacologically active. The quantum chemical calculations indicated that these complexes have the highest predisposition to undergo a nucleophilic attack followed by the NO+ release. The results allowed us to interpret the metabolism of the [M(CN)xNOy]n- complexes in terms of the NO(+)-donation.
International Immunopharmacology | 2016
Andrzej Jakubowski; Magdalena Sternak; Konrad Jabłoński; Marta Ciszek-Lenda; Janusz Marcinkiewicz; Stefan Chlopicki
We have recently demonstrated that concanavalin A (Con A)-induced hepatitis is associated with the release of endogenous 1-methylnicotinamide (MNA). Here we study the mechanism by which exogenous MNA alleviates Con A-induced liver inflammation and injury in vivo. The involvement of prostacyclin (PGI2) in hepatoprotective action of MNA (30-100 mg kg(-1); i.v.) was studied by the use of IP receptor antagonist RO3244794 (10 mg kg(-1); p.o.) given prior to Con A (5-20 mg kg(-1); i.v.). Liver damage was assessed by measurements of: liver specific transaminases in plasma (alanine aminotransferase; aspartate aminotransferase); cytokines release (IL-4, IFN-γ and TNF-α); liver histopathology; and 24h survival rates. Additionally, the effect of a stable analog of prostacyclin (carbaprostacyclin) on IL-4, IFN-γ and TNF-α production by isolated spleen lymphocytes in response to Con A was analyzed. MNA diminished Con A-induced rise in liver specific transaminases, alleviated histopathological injury and improved 24h survival rates, the latter effect in a degree comparable with the pretreatment of animals with dexamethasone (0.5 mg kg(-1); i.p.). MNA inhibited also a rise in IL-4 and TNF-α concentration in plasma measured 2 h after Con A administration, while IFN-γ was less affected. The effects of MNA were reversed by pretreatment with IP antagonist RO3244794. In isolated spleen lymphocytes, carbaprostacyclin profoundly decreased production of IL-4, the effect on TNF-α was modest with no effect on IFN-γ production. In conclusion, MNA attenuated Con A-induced hepatitis by a prostacyclin-dependent mechanism involving the inhibition of lymphocytes-derived IL-4 and the inhibition of Kuppfer-cells derived TNF-α.
International Immunopharmacology | 2015
Magdalena Sternak; Andrzej Jakubowski; Elżbieta Czarnowska; Ewa M. Slominska; Ryszard T. Smolenski; Malgorzata Szafarz; Maria Walczak; Barbara Sitek; Tomasz Wojcik; Agnieszka Jasztal; Karol A. Kamiński; Stefan Chlopicki
Exogenous 1-methylnicotinamide (MNA) displays anti-inflammatory activity. The aim of this work was to characterize the profile of release of endogenous MNA during the initiation and progression of murine hepatitis induced by Concanavalin A (ConA). In particular we aimed to clarify the role of interleukin-6 (IL-6) as well as the energy state of hepatocytes in MNA release in early and late phases of ConA-induced hepatitis in mice. Hepatitis was induced by ConA in IL-6(+/+) and IL-6(-/-) mice, and various parameters of liver inflammation and injury, as well as the energy state of hepatocytes, were analysed in relation to MNA release. The decrease in ATP/ADP and NADH/NAD ratios, cytokine release (IL-6, IFN-ɤ), acute phase response (e.g. haptoglobin) and liver injury (alanine aminotransaminase, ALT) were all blunted in ConA-induced hepatitis in IL-6(-/-) mice as compared to IL-6(+/+) mice. The release of MNA in response to Con A was also significantly blunted in IL-6(-/-) mice as compared to IL-6(+/+) mice in the early stage of ConA-induced hepatitis. In turn, nicotinamide N-methyltransferase (NNMT) and aldehyde oxidase (AO) activities were blunted in the liver and MNA plasma concentration was elevated to similar degree in the late stage after Concanavalin A in IL-6(+/+) and IL-6(-/-) mice. In conclusion, we demonstrated that in ConA-induced hepatitis, early, but not late MNA release was IL-6-dependent. Our results suggest that in the initiation and early hepatitis, MNA release is linked to the energy deficit/impaired redox status in hepatocytes, while in a later phase, MNA release is rather linked to the systemic inflammation.
European Journal of Pharmacology | 2008
Krzysztof Bryniarski; Rafał Biedroń; Andrzej Jakubowski; Stefan Chlopicki; Janusz Marcinkiewicz
Prostaglandins Leukotrienes and Essential Fatty Acids | 2005
Andrzej Jakubowski; Stefan Chlopicki; Rafał Olszanecki; Jawień J; Magdalena Lomnicka; Dupin Jp; Gryglewski Rj
Liebigs Annalen | 1996
Jacek Mlochowski; Leszek Juchniewicz; Krystian Kloc; Gryglewski Rj; Andrzej Jakubowski; Anna D. Inglot
Naunyn-schmiedebergs Archives of Pharmacology | 2009
Andrzej Jakubowski; N. Maksimovich; R. Olszanecki; A. Gebska; Harald Gasser; Bruno K. Podesser; Seth Hallström; Stefan Chlopicki
Physiological Research | 1996
Gryglewski Rj; Stefan Chlopicki; Niezabitowski P; Andrzej Jakubowski; Magdalena Lomnicka